Amylyx Pharmaceuticals, Inc. 4

CFO James M. Frates of Amylyx Pharmaceuticals, Inc. sold 10,810 shares of AMLX common stock on 2026-09-10 in automatic, tax-withholding-related transactions following PSU vesting.

On September 10, 2026, Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates sold a total of 10,810 shares of Amylyx common stock in two open market transactions, consisting of 9,768 shares at a weighted average price of approximately $32.27 and 1,042 shares at a weighted average price of approximately $33.23. The Form 4 footnotes state that these sales were automatic transactions executed solely to cover tax withholding obligations arising from the vesting of performance stock units and were not discretionary sales by the insider. Following these transactions, Frates held 233,625 shares directly, and additional shares were held indirectly through several trusts (including grantor retained annuity trusts and an irrevocable family trust) for which he serves as trustee, with beneficial ownership of those trust holdings disclaimed except to the extent of his pecuniary interest. Using the reported sale prices as a proxy, the direct holdings are worth roughly $7.5–$7.8 million, while the indirect trust holdings total about 166,531 shares, representing an additional approximate $5.4–$5.6 million in value at similar price levels.

Filing Facts

CIK

1658551

Ticker

AMLX

Form

4

Source Type

fda

Accession

0001193125-26-390509

Alert Tier

5